Diagnosis: Immune checkpoint inhibitor dermatitis
A 62-year-old male presents with a diffuse pruritic rash six weeks after initiating pembrolizumab for metastatic melanoma. The eruption is characterized by erythematous papules and plaques involving the trunk and extremities, accompanied by significant itching. This case highlights the importance of recognizing immune-related skin toxicities associated with immune checkpoint inhibitors.
A 62-year-old male with a history of metastatic melanoma presents with a diffuse pruritic rash that developed six weeks after starting pembrolizumab. On physical examination, the patient exhibits erythematous papules and plaques on the trunk and extremities, with notable excoriations from scratching. The lesions are symmetric and do not demonstrate signs of infection.Skin findings: Erythematous papules and plaques on the trunk and extremities.Distribution: Symmetric involvement, primarily on the trunk and limbs.Itching: Significant pruritus reported by the patient.Absence of systemic symptoms: No fever, malaise, or other systemic involvement noted.Inspection of lesions: No pustules, vesicles, or crusting observed.
The rash began approximately six weeks after the patient started treatment with pembrolizumab for metastatic melanoma. There were no known triggers, and the patient had not experienced similar skin reactions in the past. He has no significant past medical history, and there is no family history of autoimmune diseases. Social history is notable for occasional sun exposure, but no recent travel or new medications aside from pembrolizumab.Onset: Rash developed six weeks post-initiation of anti-PD-1 therapy.Prior treatments: No topical or systemic treatments attempted prior to presentation.Past medical history: History of metastatic melanoma, otherwise unremarkable.Family history: No autoimmune conditions reported in the family.Social history: No recent travel; occasional sun exposure.
Acute / First-Line ManagementTopical corticosteroids: High-potency steroids (e.g., clobetasol propionate 0.05% cream applied twice daily) may be used to reduce inflammation and pruritus.Antihistamines: Oral antihistamines (e.g., cetirizine 10 mg daily) can be administered to alleviate itching.Moisturizers: Emollient creams should be applied to maintain skin hydration.Workup and Diagnostic ConfirmationClinical diagnosis based on history and examination findings, supplemented by the assessment of response to treatment.Consideration of skin biopsy if lesions do not respond to initial management or if there is diagnostic uncertainty.Long-Term ManagementMonitor for potential progression of skin reactions; if severe, consider dose modification or discontinuation of pembrolizumab.Referral to dermatology for persistent or severe cases, especially if systemic therapy is required.Patient education regarding the recognition of skin reactions and the importance of timely reporting.
Contact Dermatitis: Presents with localized pruritus and erythema, often related to specific exposures; history of new products or environmental changes is key.Drug Eruption: Can occur with a variety of medications, typically presents as widespread rash; history of other medications is critical.Psoriasis: Characterized by well-defined plaques with silvery scale; may have family history and chronicity.Atopic Dermatitis: Pruritic lesions may be present; often associated with personal or family history of atopy.Urticaria: Presents with wheals and is transient; often triggered by food, medication, or stress.Seborrheic Dermatitis: Often involves the scalp and face; characterized by greasy, yellowish scales.Viral Exanthems: Typically associated with systemic symptoms; history of recent infections may provide clues.Cutaneous T-cell Lymphoma: May present with pruritic plaques or patches; requires biopsy for confirmation.
High-Yield PearlsRecognition: Early identification of immune-related dermatologic toxicities is crucial for timely management.Clinical Features: Immune checkpoint inhibitor dermatitis commonly presents as a pruritic rash, often resembling eczema or psoriasis.Management: Topical corticosteroids and antihistamines are first-line treatments for mild to moderate cases.Severity Assessment: Monitor the severity of skin reactions to determine if systemic therapies or modifications to treatment are necessary.Patient Education: Inform patients about potential skin reactions and the importance of reporting them promptly.Immune checkpoint inhibitors can lead to significant dermatologic side effects; vigilance is key to effective management.
Tags: checkpoint inhibitor, ICI dermatitis, drug reaction